top of page
  • Writer's pictureOrange Biomed

Orange Biomed Talks Expanding U.S. Collaborations with Leaders like Mayo Clinic Laboratories


DAC Premier Healthcare Event Day 1 - Orange Biomed with Dr. Morice asking questions.

DAC Premier Healthcare Event Day 1 - Orange Biomed with Dr. Morice asking questions.


On February 1st, 2023, in Seoul, Orange Biomed attended the DAC Global Bridge Series Premier Healthcare Event hosted by BDMT Global. The three-day event centered on increasing digitization, automation, and cross-industry collaboration opportunities.


Day 1 - Connecting with the U.S. Healthcare Ecosystem

Day 1 - Connecting with the U.S. Healthcare Ecosystem


On the first day of the event, Orange Biomed enjoyed listening to several keynote speakers. All speakers are thought leaders from the U.S. healthcare industry, from patient advocates to healthcare professionals to CEOs.


Developing industry connections and gaining insights from key healthcare players is vital to Orange Biomed as we establish ourselves in the U.S. in 2023.



Day 2 -  Special Selection for DAC Pitchfest, Sponsored by Mayo Clinic Laboratories

Day 2 - Special Selection for DAC Pitchfest, Sponsored by Mayo Clinic Laboratories


BDMT Global individually selected Orange Biomed to participate in the Mayo Clinic Laboratories-sponsored Pitchfest business pitch collaboration session.


Our participation aimed to form mutually beneficial collaborations with U.S. and global leaders that fulfill current healthcare gaps, such as Mayo Clinic Laboratories.

Mayo Clinic Laboratories is a diagnostic lab that conducts in-house tests and studies. The clinic has 3,800 tests and pathology services and 4,500 Mayo Clinic physicians and scientists available for consultation. Their specialties include cardiology, endocrinology, genetics, gastroenterology, microbiology and infectious diseases, and more.


During Pitchfest, Orange Biomed spoke directly to the President and CEO of Mayo Clinic Laboratories, Dr. William Morice. Our Orange Biomed team of speakers–Co-President Yeaseul Park, Co-President Unghyeon Ko, and Head of U.S. Business Luke Jo–presented Orange Biomed’s technology and prototype of OBM rapid A1c.



Our Mission for 2023 and Beyond

Our Mission for 2023 and Beyond


Orange Biomed’s mission is to help reduce the diabetes crisis in the U.S. by providing accurate, affordable, and accessible diabetes management A1c measurement devices for all.


We are eager to continue participating in events that will allow us to connect with U.S. healthcare professionals and players.


Find us next at the ADA’s 83rd Scientific Sessions in San Diego, CA, June 23-26, for the premier meeting in diabetes.


Source:



Comments


Commenting has been turned off.
bottom of page